/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Immuneering Corp

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$6.7723 0.0075(0.75%) IMRX at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 6.43
Highest Today 6.78
Today’s Open 6.68
Prev. Close 6.69
52 Week High 10.08
52 Week Low 1.10
Day’s Range: Low 6.43 High 6.78
52-Week Range: Low 1.10 High 10.08
1 day return -
1 Week return -11.76
1 month return +5.96
3 month return +23.4
6 month return +242.63
1 year return +193.47
3 year return +10.38
5 year return -
10 year return -

Institutional Holdings

Vanguard Group Inc 2.48

Vanguard Total Stock Mkt Idx Inv 1.66

Marshall Wace Asset Management Ltd 1.35

BlackRock Inc 0.99

Fidelity Select Biotechnology 0.90

Vanguard Institutional Extnd Mkt Idx Tr 0.63

SOUTHPORT MANAGEMENT, L.L.C. 0.57

Geode Capital Management, LLC 0.54

FMR Inc 0.52

Morgan Stanley - Brokerage Accounts 0.47

HighTower Advisors, LLC 0.32

Fidelity Extended Market Index 0.32

State Street Corp 0.23

Bridgeway Capital Management, LLC 0.22

Extended Equity Market Fund K 0.18

TD Health Sciences - I 0.18

CI Private Wealth LLC 0.15

iShares Micro-Cap ETF 0.15

Millennium Management LLC 0.15

Bridgeway Ultra-Small Company Market 0.12

Fidelity Total Market Index 0.11

Tidemark LLC 0.10

Fidelity Series Total Market Index 0.10

Northern Trust Corp 0.09

JHFunds2 Health Sciences NAV 0.08

First Manhattan Co. LLC 0.08

Flower City Capital 0.08

Spartan Extended Market Index Pool F 0.07

Cubist Systematic Strategies, LLC 0.07

Bank of America Corp 0.07

XTX Topco Ltd 0.06

Avantis US Small Cap Equity ETF 0.05

Alethea Capital Management, LLC 0.05

Vanguard Balanced Index Inv 0.05

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - L 0.04

Vanguard Instl Ttl Stck Mkt Idx Tr 0.04

Vanguard Instl Ttl Stk Mkt Idx InstlPls 0.04

NT Ext Equity Mkt Idx Fd - NL 0.04

Spartan Total Market Index Pool G 0.04

Market Status

Strong Buy: 2

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 431.97 M

PB Ratio 2.1695

PE Ratio 0.0

Enterprise Value 270.96 M

Total Assets 52.71 M

Volume 585485

Company Financials

Annual Revenue FY23:455 0.0M, FY22:316952 0.3M, FY21:2079961 2.1M, FY20:2311535 2.3M, FY19:1919709 1.9M

Annual Profit FY23:455 0.0M, FY22:158830 0.2M, FY21:926888 0.9M, FY20:1031210 1.0M, FY19:696739 0.7M

Annual Net worth FY23:-51633691 -51.6M, FY22:-49281797 -49.3M, FY21:-33535748 -33.5M, FY20:-17039898 -17.0M, FY19:-8060750 -8.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-86158 -0.1M, Q2/2025:-91844 -0.1M, Q1/2025:-175761 -0.2M, Q3/2024:null 0.0M, Q2/2024:-175482 -0.2M

Quarterly Net worth Q3/2025:-14964875 -15.0M, Q2/2025:-14433881 -14.4M, Q1/2025:-15046132 -15.0M, Q3/2024:-14597366 -14.6M, Q2/2024:-14079927 -14.1M

Fund house & investment objective

Company Information Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 54

Industry Biotechnology

CEO Dr. Benjamin J. Zeskind M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow